Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    Footer revision updated to v3.4.3; the previous v3.4.2 label was removed.
    Difference
    0.0%
    Check dated 2026-03-07T20:09:17.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    Footer now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1.
    Difference
    0.0%
    Check dated 2026-02-14T04:38:46.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    Revision reflects an update from v3.4.0 to v3.4.1 with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-02-07T00:49:01.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    Added Show glossary / Hide glossary options and updated metadata labels to reflect Revision: v3.4.0 (Last Update Submitted that Met QC Criteria; No FEAR Act Data).
    Difference
    0.3%
    Check dated 2026-01-23T18:27:30.000Z thumbnail image
  7. Check
    60 days ago
    Change Detected
    Summary
    Revision: v3.3.4 appears alongside the previous v3.3.3 revision, indicating a small maintenance update with no impact on the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-16T12:32:01.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    Locations section reorganized to include a Colorado entry under a general Locations header; the Colorado Locations subheading was removed, and the revision label updated to v3.3.3 with the HHS Vulnerability Disclosure link removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-18T21:37:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.